OLFM4 and cancer: This hypothesis is consistent with recent work that showed that serum OLFM4 levels were elevated in e4 carriers, and positively correlated with cognitive decline and with brain atrophy.[42] OLFM4 is a well‐studied marker of many cancers, and the inhibition of this target should be well characterized.